Intermune (NASDAQ: [[ticker:ITMN]]), the Brisbane, CA-based maker of a drug for a deadly lung disease called pulmonary fibrosis, said today that it has won a positive recommendation for its treatment from a panel of expert advisors to European Union regulators. The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended that Intermune’s pirfenidone (Esbriet) be cleared for sale in Europe. Shares of the company more than doubled today on the news, rocketing to $34.05 a share at 1:21 pm Eastern today. The news came after Intermune failed to win approval from U.S. regulators back in May.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
